Project Grant R21DA064020
Award Date 9/1/26
Completion Date 7/31/28
Dollars Obligated $191K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pittsburgh, PA 15213, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Johns Hopkins University $631,094 on August 1, 2026, for research evaluating the neurocognitive, psychomimetic, and abuse-related effects of emerging psychoactive cannabinoids under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year project (August 1, 2026 through June 30, 2031) examining vaporized delta-8 tetrahydrocannabinol (D8-THC) and hexahydrocannabinol (HHC)—novel cannabinoids marketed as legal...
- The National Institute on Drug Abuse awarded Carnegie Mellon University $217,672 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to measure how addiction-associated genetic variants regulate gene expression across specific brain regions in response to opioids and cocaine. The research measures regulatory activity of candidate human addiction-associated genetic enhancers in the striatum, cortex, hippocampus, and amygdala of mice using in vivo massively parallel...
- The National Institute on Drug Abuse awarded Washington State University $420,750 on July 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate the neurobiological substrates of cannabis-seeking behavior through preclinical research models. The funded research combines fiber photometry and wireless recording techniques to examine how dynamic neural activity and dopamine release in corticostriatal circuits—specifically the medial prefrontal cortex and nucleus...
- The National Institute on Drug Abuse awarded The Johns Hopkins University $708,190 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 1, 2026, to conduct double-blind, placebo-controlled human laboratory studies examining the pharmacokinetic and pharmacodynamic effects of varying tetrahydrocannabinol (THC) and cannabidiol (CBD) ratios in cannabis edibles. Research Aim 1 will evaluate how different THC:CBD ratios—including 1:0, 1:1, 1:5, 1:10, 1:30, and 0:1—affect THC...
- The National Institute on Drug Abuse awarded Auburn University $173,128 on November 29, 2025, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support training and experimental research on the neurobiological mechanisms underlying cannabis use disorder. The project, titled "Experimental Manipulation of the Emotional Salience of Cannabis Use-Related Information," will provide training in transcranial magnetic stimulation (TMS) methodology, magnetic resonance imaging...
- The National Institute on Drug Abuse awarded The Leland Stanford Junior University $160,840 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate TRPV1-mediated vascular and neuronal dysregulation induced by natural and synthetic cannabinoids. The research examines differential impacts of natural cannabinoids (cannabidiol, delta-9-tetrahydrocannabinol) and synthetic cannabinoids (cannabinol, hexahydrocannabinol) on vascular and neuronal function, with...
- The National Institute on Drug Abuse (NIDA) awarded The Johns Hopkins University $718,124 on September 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate chronic cannabinoid vapor exposure effects on the brain and behavior. The research examines whether repeated exposure to vaporized delta-9-tetrahydrocannabinol (THC) causes lasting behavioral and neurological alterations in adult male and female rats, including disrupted neural connectivity, white matter...
- The National Institute on Drug Abuse awarded the University of Illinois $726,413 under the Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026, for a Project Grant to examine neural and computational markers of reward processes as longitudinal risk markers of cannabis use escalation in young adults with anhedonia. The research investigates how acute laboratory administration of delta-9-tetrahydrocannabinol (D9-THC) versus placebo affects reward processing in individuals aged...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $207,792 on August 1, 2026, to examine sex differences in the endocannabinoid system and their contribution to differential THC-associated reward in individuals with cannabis use disorder. The research employs a multi-modal human laboratory paradigm involving 134 adults with cannabis use disorder. Participants will undergo pharmacogenetic screening to identify endocannabinoid-related genetic polymorphisms in...
- The National Institute on Drug Abuse awarded Washington State University $639,915 on February 15, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to interrogate the mechanistic underpinnings of cognitive inflexibility in cannabis-exposed offspring. The research employs a novel, translationally relevant model of cannabis vapor exposure in pregnant rat dams, using custom-designed equipment to deliver discrete puffs of vaporized, plant-derived cannabis extracts in a...